Aimei Health Technology (NASDAQ:AFJK) Stock Rating Upgraded by Wall Street Zen

Aimei Health Technology (NASDAQ:AFJK) was upgraded by Wall Street Zen to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings cut shares of Aimei Health Technology from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, August 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Aimei Health Technology Price Performance

AFJK stock opened at $12.10 on Friday. Aimei Health Technology has a 52-week low of $6.75 and a 52-week high of $130.37. The stock’s 50 day moving average is $12.10 and its two-hundred day moving average is $26.90. The company has a market capitalization of $38.36 million, a PE ratio of 201.70 and a beta of 0.85.

Aimei Health Technology (NASDAQ:AFJK) last announced its earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Institutional Trading of Aimei Health Technology

A hedge fund recently raised its stake in Aimei Health Technology stock. Clear Street Group Inc. raised its position in shares of Aimei Health Technology Co., Ltd. (NASDAQ:AFJK) by 36.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 83,337 shares of the company’s stock after buying an additional 22,294 shares during the quarter. Clear Street Group Inc. owned about 1.36% of Aimei Health Technology worth $5,334,000 at the end of the most recent quarter. Institutional investors and hedge funds own 45.58% of the company’s stock.

Aimei Health Technology Company Profile

Aimei Health Technology Co, Ltd. (NASDAQ: AFJK) is a special purpose acquisition company (SPAC). Rather than operating a traditional health-care business, the company was established to identify and complete a merger, acquisition, or similar business combination with an operating company.

The company’s stated focus is expected to include businesses in the health-care and health-technology sectors. Before completing a transaction, Aimei Health Technology does not have a broad portfolio of products or services and may have limited operating activity beyond pursuing a suitable target and managing its corporate structure.

Aimei Health Technology is incorporated in the Cayman Islands and trades in the United States.